Kaleido BioSciences Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
76
- Latest Deal Type
-
Out of Business
Kaleido BioSciences General Information
Description
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Contact Information
Website
www.kaleido.comCorporate Office
- 65 Hayden Avenue
- Lexington, MA 02421
- United States
Corporate Office
- 65 Hayden Avenue
- Lexington, MA 02421
- United States
Kaleido BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 08-Apr-2022 | Completed | Out of Business | |||
| 5. Merger/Acquisition | 10-Feb-2021 | Completed | Generating Revenue | |||
| 4. IPO | 28-Feb-2019 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 25-Jun-2018 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series B) | 18-Sep-2017 | $37.1M | $41.6M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 13-Aug-2015 | $4.5M | $4.5M | Completed | Stealth |
Kaleido BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 3,057,972 | $0.001000 | 8% | $1.69 | $1.69 | 1x | $1.69 | 4.69% |
| Series A | 14,469,180 | $0.001000 | 8% | $0.73 | $0.73 | 1x | $0.73 | 22.21% |
Kaleido BioSciences Comparisons
Industry
Financing
Details
Kaleido BioSciences Competitors (46)
One of Kaleido BioSciences’s 46 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA |
Kaleido BioSciences Patents
Kaleido BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230165881-A1 | Oligosaccharide compositions and methods of use thereof for treating viral infections | Pending | 30-Apr-2020 | ||
| AU-2020267774-A1 | Oligosaccharide compositions and methods of use | Inactive | 08-May-2019 | ||
| CA-3138903-A1 | Oligosaccharide compositions and methods of use thereof | Pending | 08-May-2019 | ||
| US-20200221587-A1 | Flexible display and electronic device including the same | Active | 09-Jan-2019 | ||
| US-11197380-B2 | Flexible display and electronic device including the same | Active | 09-Jan-2019 | G06F1/1652 |
Kaleido BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kaleido BioSciences ESG
Risk Overview
Risk Rating
Updated July, 01, 2022
41.78 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Pharmaceuticals
Subindustry
of 473
Rank
Percentile
Kaleido BioSciences FAQs
-
When was Kaleido BioSciences founded?
Kaleido BioSciences was founded in 2015.
-
Where is Kaleido BioSciences headquartered?
Kaleido BioSciences is headquartered in Lexington, MA.
-
What is the size of Kaleido BioSciences?
Kaleido BioSciences has 76 total employees.
-
What industry is Kaleido BioSciences in?
Kaleido BioSciences’s primary industry is Drug Discovery.
-
Is Kaleido BioSciences a private or public company?
Kaleido BioSciences is a Private company.
-
What is Kaleido BioSciences’s current revenue?
The current revenue for Kaleido BioSciences is .
-
How much funding has Kaleido BioSciences raised over time?
Kaleido BioSciences has raised $218M.
-
Who are Kaleido BioSciences’s competitors?
Amgen, Enterome, Vedanta Biosciences, Seres Therapeutics, and Meditope Biosciences are some of the 46 competitors of Kaleido BioSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
